The OneRNA® Platform
By analyzing RNA we can monitor health, detect disease, and design next-generation cures
What is the difference between RNA and DNA?
RNA is the software of the cell and can inform us of the actual presence of disease, whereas DNA is the hardware and mainly informs us of the risk of disease. DNA panels used in cancer tissue analyses up to 500 genes typically only identify one drug in up to 40% of the cases.
We don't like guessing, and therefore we analyze ALL the +20,000 mRNA’s in the sample. This makes our OneRNA® platform the most powerful platform in the industry and it enables the implementation of AI into standard of care. They was y we built it is tissue and disease agnostic and exponentially scalable.
RNA is coding for proteins and proteins are targets for drugs. Today RNA is directly a target for drugs and a drug itself.
We are pioneers in analyzing RNA using sequencing and our OneRNA® test has been validated in breast and ovarian cancer and identifies multiple treatment options and/or clinical studies for practically all patients.
We are now developing methods to rapidly translate RNA Code to RNA Therapeutics to further individualize treatment.
When making treatment decisions, knowledge is power.
A cancer diagnosis is life-changing. Ask your doctor about the testing options, including our OneRNA® test in breast and ovarian cancer. OneRNA® analyses all mRNA in your tumor’s tissue, which may help individualize a treatment plan. Because no drugs are effective in all patients, it's essential to have a plan for the next steps.
WHO WE ARE
Experienced Management Team with Startup RNA
Gitte Pedersen
CEO and co-founder
Gitte Pedersen, CEO is a former executive at Novo Nordisk. She has advised the Danish Government and early-stage biotech companies regarding their corporate development in the US
Follow at Linkedin
Morten Pedersen
CSO and cofounder
Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very strong innovation track record with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies
Jesper Zeuthen
VP Oncology research
Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.
Articles, Grants, Investors and Customers
These are our supporters, funders and customers
Grant
Genome Danmark
Accelerator
Impact Investor
Investor
Impact Investor
#2 at WFN
Top 10 XTC
Horizon2020 grant
Eurostars Grant
MedTech Innovator Top 50
Winner of the Lyfebulb-Helsinn Award
Winner of the EIC Lifescience Award
Featured in Forbes
Won EUTop50 and invited to present at the European Parliament
Presented at GSTIC addressing the UN sustainability goals in health
Finals of the Blue Cross Blue Shields GuideWell competition for novel COVID19 solutions
In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar, 6-month competition to develop faster, cheaper, and easier to COVID-19 testing methods at scale.
XPrize Semifinalist Targets 300 Million Tests Per Day With Scalable COVID Self-Test
YOU + SOCIAL MEDIA
= SOCIAL IMPACT
You're awesome. Let's talk.
